INS and Alzheimer disease: At the molecular level, the lower glucose utilization in AD patients has been associated with alterations, including decreased expression of GLUT1, -3 and -4 in the cortex and hippocampus, insulin resistance in the brain, mitochondrial dysfunction, deregulation of the Krebs cycle, and oxidative phosphorylation, which are triggered by the loss of key enzymes (81–83).